IDEX Corporation — Q3 2020 Form 10-Q
Business context and reporting period. IDEX designs and manufactures fluid and metering technologies, health and science technologies, and fire, safety and diversified products. This unaudited report covers the three and nine months ended September 30, 2020; comparisons are with the corresponding 2019 periods. The company reported that COVID-19 and related economic effects reduced customer demand, though its facilities generally remained operational.
Financial performance
| Metric | Q3 2020 | Q3 2019 | Nine months 2020 | Nine months 2019 |
|---|---|---|---|---|
| Net sales | $581.1 million | $624.2 million | $1,736.8 million | $1,888.6 million |
| Gross profit / margin | $251.5 million / 43.3% | $282.0 million / 45.2% | $758.3 million / 43.7% | $858.1 million / 45.4% |
| Operating income / margin | $131.2 million / 22.6% | $141.8 million / 22.7% | $381.7 million / 22.0% | $444.8 million / 23.6% |
| Net income | $103.8 million | $105.2 million | $276.7 million | $328.7 million |
| Diluted EPS | $1.37 | $1.37 | $3.64 | $4.30 |
| Operating cash flow | $153.7 million | $157.1 million | $407.9 million | $376.9 million |
| Free cash flow (non-GAAP) | $135.3 million | $146.0 million | $368.5 million | $340.1 million |
- Q3 sales fell 7%; organic sales declined 12%, partly offset by acquisitions (4%) and foreign exchange (1%). Nine-month sales fell 8%, with organic sales down 11% and acquisitions contributing 3%.
- Management reported Q3 EBITDA of $153.3 million (26% of sales) and adjusted EBITDA of $156.2 million (27%). Nine-month EBITDA was $436.4 million (25%); adjusted EBITDA was $455.7 million (26%). These are non-GAAP measures.
- Q3 adjusted EPS was $1.40, down 8% year over year; nine-month adjusted EPS was $3.84, down 14%, according to the filing’s non-GAAP reconciliation.
Segments and material changes
- Fluid & Metering Technologies: Q3 sales decreased 8% and operating income decreased to $58.4 million from $77.5 million; margin fell to 26.5% from 32.2%. Nine-month sales fell 9% and operating income fell to $176.1 million from $223.5 million. Lower industrial and energy activity, COVID-related demand weakness and project delays weighed on results.
- Health & Science Technologies: Q3 sales fell 4%, but operating income rose to $49.9 million from $40.2 million and margin improved to 22.6% from 17.5%, mainly reflecting prior-year impairment and inventory step-up charges and current cost actions. Nine-month sales fell 4%; operating income was nearly flat at $150.6 million.
- Fire & Safety/Diversified Products: Q3 sales declined 9% and operating income declined to $37.1 million from $42.0 million; margin was 26.3% versus 27.2%. Nine-month sales fell 13% and operating income declined to $104.0 million from $125.9 million.
- Across the company, lower volume and mix compressed gross margin. SG&A declined with cost controls, restructuring savings and lower variable costs. Nine-month reported results also included a $4.1 million Flow MD inventory step-up charge and an $8.4 million loss on early redemption of debt; restructuring expense was $6.8 million versus $14.1 million a year earlier.
Cash, debt and liquidity
- At September 30, 2020, cash and cash equivalents were $877.8 million, total borrowings were $1,050.3 million, and shareholders’ equity was $2,396.5 million. The company had $793.0 million of available revolving-credit capacity after letters of credit. Management described total liquidity as over $1.6 billion and gross leverage as 1.7x.
- Nine-month operating cash flow increased 8% to $407.9 million, supported by working capital despite lower earnings. Capital expenditures were $39.4 million; business acquisitions used $118.2 million, principally for Flow Management Devices.
- IDEX issued $500 million of 3.0% senior notes due 2030 and used proceeds to redeem $300 million of 4.5% notes due 2020, paying a make-whole premium. At quarter-end, the company reported compliance with its financial covenants and an interest coverage ratio of 14.6x.
- Cash dividends paid were $114.2 million and share repurchases were $110.3 million during the first nine months. The board authorized an additional $500 million of repurchases in March; $712.0 million remained authorized at September 30.
Outlook, risks and unusual items
- Management expected organic sales to decline approximately 3%–5% in Q4 2020. It expressed confidence in cash and financing availability for the foreseeable future, while cautioning that the duration and effects of COVID-19 were uncertain. No full-year earnings guidance was provided in the supplied filing text.
- Risks cited include further COVID-19-related demand deterioration, facility or supplier disruption, customer credit losses, reduced industrial activity and capital spending, foreign-exchange movements, tariffs, acquisition integration, and possible increases in borrowing or capital costs.
- The company recognized an $8.4 million early-debt-redemption loss in the nine-month period. It also recorded restructuring costs and an acquisition-related inventory step-up. The 2020 interim impairment test of certain definite-lived intangible assets found no impairment.
- IDEX said ordinary-course legal proceedings were not expected to have a material adverse effect. It disclosed asbestos-related lawsuits; most resolved claims had been dismissed or settled for immaterial amounts, and the company stated it did not currently expect material adverse impact, while noting uncertainty about future insurance coverage.
- Disclosure controls were evaluated as effective at quarter-end; the filing reported no material change in internal control over financial reporting during the quarter.
Key facts investors should verify
- Whether the anticipated Q4 organic sales decline of 3%–5% materialized, and how demand and margins recovered after the reporting date.
- How much of cash generation and liquidity remains available after dividends, repurchases, acquisitions and debt service, including the location and accessibility of cash held outside the U.S.
- Whether COVID-related customer, supplier or operational disruptions affected collectability, production, or the company’s ability to meet its outlook.
- Segment-level trends, particularly continued weakness in Fluid & Metering and Fire & Safety, versus improvement in Health & Science profitability.
- The effect of acquisition integration and purchase-accounting charges, and the progression of restructuring savings and costs.
- Debt covenant headroom, upcoming maturities and any changes in financing costs or revolving-credit access.